Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC With Carboplatin in Platinum-sensitive Recurrent Ovarian Cancer
NCT02487849Phase 2Withdrawn
- Sponsor
- Ordensklinikum Linz Barmherzige Schwestern
- Start
- Aug 2016
- Primary completion
- Aug 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Ordensklinikum Linz Barmherzige Schwestern. Planned start Aug 2016; status: withdrawn.
02
Drugs
carboplatin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02487849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487849.